Israel Active

Israel’s Skip Therapeutics is partnering with Sheba Medical Center to develop ASO-based (short RNA sequences) treatments for rare genetic diseases. Skip's ASOs (Antisense Oligonucleotide) aim to restore the function of mutated genes in genetic disorders.

Israel’s Amorphical (see previously) has adapted its amorphous calcium carbonate production technology to treat inflammatory diseases such as Crohn’s disease, multiple sclerosis, and arthritis. The mineral neutralizes the acidity within affected tissue to prevent inflammation.

Scientists at the Hebrew University of Jerusalem have discovered how DNA methylation acts as a gene control system, like a traffic light that can modulate gene activity and trigger or prevent cancer mutations. It will help develop personalized therapies for cancer patients.

Israel’s Epitomee has completed clinical trials of its ingestible pill that opens up in the stomach to produce a feeling of satiety. In 24 weeks the 140 participants who swallowed the pill lost up to 15% of their body weight, with no side effects.  Epitomee intends to apply for FDA approval in 2024.

Israel’s Exosomm extracts tiny capsules of microRNA called exosommes from cows’ milk. They then add them as a powder to food as a treatment for colitis and Crohn’s. Successful laboratory trials have led to recruitment for clinical trials at Hadassah Medical Center in Jerusalem.

The International Fellowship of Christians and Jews has funded a 100-patient Emergency Operations Center in a fortified sheltered area of Emek Medical Center in the Galilee. The IFCJ is also funding a 50-patient fortified space in the hospital’s oncology building.

Some 200 Israeli medical students were studying overseas but returned to join the IDF. Israel’s Ministry of Health has requested the deans of Israeli medicine faculties to help to integrate these students in Israeli hospitals and medical schools at the end of the war.

An additional NIS 650 million will be added to Israel's health basket as part of the war efforts.

Stanford Institute for Stem Cell Biology and Regenerative Medicine is to using the AML(acute myeloid leukemia) detection kits from Israel’s Sequentify (see previously) in its leukemia research. Sequentify's Infiniseq technology cuts DNA sequencing time to only 3.5 hours.

Israel’s Medial EarlySign (see previously) has partnered US-based Geisinger to identify patients at high risk for respiratory or pulmonary diseases such as lung cancer. Their LungFlag AlgoMarker analyzes data from a patient’s electronic health record to enable early screening.